FMC stock holds on Fresenius Medical Care earnings progress
Published on 07/27/2026 at 09:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
FMC stock reflects Fresenius Medical Care AG (ISIN DE0005785802) after the company reported full-year 2025 revenue of EUR 19.4 billion and net income of EUR 477 million, while 2025 operating income reached EUR 1.9 billion. Those figures frame the shares even without a fresh event-specific update in this call.
2025 revenue and profit
Fresenius Medical Care said 2025 revenue came in at EUR 19.4 billion, compared with EUR 19.2 billion in 2024, while net income rose to EUR 477 million from a 2024 loss of EUR 1.0 billion. The swing is the key comparison in the latest published numbers and gives the stock a clear financial reference point.
Operating income for 2025 was EUR 1.9 billion, and the company also reported that its operating margin improved to 9.8% from 8.5% in the prior year. That margin change is the most useful profit indicator for investors assessing whether earnings quality is still improving.
Margin up to 9.8%
The margin gain matters because it shows that Fresenius Medical Care converted a larger share of revenue into operating profit in 2025. A 1.3 percentage point move in margin is material in a dialysis business where treatment volumes, staffing, and reimbursement discipline all matter.
The company’s 2025 figures also show a turn from loss to profit at the bottom line. Net income moving from negative EUR 1.0 billion in 2024 to positive EUR 477 million in 2025 gives the stock a sharper earnings backdrop than a simple revenue comparison would suggest.
Dialysis scale remains large
Fresenius Medical Care is the world’s largest dialysis provider and reported 2025 global treatment volume in the millions of sessions across its network. The scale matters because the company’s earnings profile still depends on the interaction of patient volume, treatment mix, and cost control.
For investors, the 2025 operating income of EUR 1.9 billion is the cleaner number than revenue alone, because it reflects how much of that treatment scale translated into profit. The 2025 margin of 9.8% shows the business is still in recovery mode rather than fully normalized.
Fresenius Medical Care services
Fresenius Medical Care’s core business is dialysis care and related products, including treatment services and equipment used in kidney failure care. That mix keeps the company tied to recurring demand, but also to reimbursement and clinical cost pressure.
The 2025 report numbers remain the most relevant product and service reference for FMC stock: EUR 19.4 billion in revenue, EUR 1.9 billion in operating income, and EUR 477 million in net income. Those three figures define the current fundamental picture more clearly than a broad company profile would.
Shares and valuation
The stock level is not included here because no dated market quote was evidenced in the available search results. The financial reference point therefore rests on the 2025 report, which shows revenue up EUR 0.2 billion year on year and net income improving by EUR 1.477 billion from the prior year.
That is enough to keep FMC stock anchored to a measurable recovery story: higher revenue, a stronger margin, and a decisive swing back to profit in 2025.
Fresenius Medical Care at a glance
- Company: Fresenius Medical Care AG
- ISIN: DE0005785802
- Ticker: XETRA: FME
- Trading venue: Xetra
- Sector / Industry: Health Care Equipment & Supplies
- Index membership: DAX
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
